Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Jazz Pharma Hits Mark with Another Narcolepsy Drug

An investigational medicine in late-stage development by Jazz Pharmaceuticals hit the mark in treating cataplexy and excessive daytime sleepiness (EDS) in adults with narcolepsy.

Read More »

Enanta Announces Positive Results of NASH Treatment Study

Enanta Pharmaceuticals Inc. announced top-line results from the biotechnology company’s ARGON-1 Phase 2a study of EDP-305 for the treatment of non-alcoholic steatohepatitis (NASH).

Read More »

Amgen Announces Positive Results From Two Phase 3 Blinctyo Studies In Pediatric Patients With Relapsed ALL

Amgen announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (20120215) showed that the primary endpoint of event-free survival was met.

Read More »

GenSight’s RESCUE Trial Shows Positive Results for Rare Eye Disease

Paris-based GenSight Biologics reported the first group of data from Week 96 of the company’s RESCUE Phase III clinical trial.

Read More »

Mallinckrodt Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of StrataGraft Regenerative Tissue

Mallinckrodt plc announced positive top-line results from the global biopharmaceutical company’s pivotal Phase 3 clinical trial of the investigational StrataGraft regenerative tissue.

Read More »

Trump signs order aimed at development of better flu vaccines

U.S. President Donald Trump signed an executive order aimed at spurring the development of better vaccines to protect against seasonal influenza as well as a potential pandemic flu outbreak.

Read More »

Researchers Develop New Class of Lung Cancer Drugs

Working with a new class of drugs called G12C KRAS inhibitors, the Francis Crick Institute and Institute of Cancer Research developed product combos to stay ahead of drug-resistant tumors.

Read More »

Biogen Halts Mid-Stage IPF Drug Trial

Days after halting Biogen’s BACE inhibitor program for Alzheimer’s disease, the Cambridge-based company stopped a clinical trial in idiopathic pulmonary fibrosis due to safety reasons.

Read More »

Novartis reports positive data in Cosentyx study

Novartis announced positive new data from a Phase III trial evaluating the efficacy and safety of Cosentyx (secukinumab) in non-radiographic axial spondyloarthritis.

Read More »

Prostate drug may be useful for Parkinson’s disease

Collaborating researchers at the University of Iowa and Capital Medical University in China found that a drug used to treat enlarged prostate, terazosin, appears able to slow the progress of Parkinson’s disease.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom